| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Tamoxifen Lowers Risk Of Invasive Breast Cancer LONDON, ENGLAND -- June 11, 1999 -- The introduction of mammography (breast screening) enabled better diagnosis of ductal carcinoma in situ (DCIS), a non-invasive cancer of the breast. Invasive cancer can develop in women who have DCIS and until the mid-1980s DCIS was treated frequently by mastectomy. Management, however, was changed after the publication of a study that showed lumpectomy plus radiation therapy to be similarly effective to mastectomy. Professor Bernard Fisher and colleagues from Canada and the United States investigated whether treatment with lumpectomy and radiation therapy could be improved further by the addition of the drug Nolvadex (tamoxifen) to help to prevent invasive disease and they report their findings in this week's issue of The Lancet. In the study, 1,804 women with DCIS were randomly assigned lumpectomy and radiation therapy, 902 women were assigned to five years of treatment with daily tamoxifen (20 mg) and 902 women assigned a placebo (an agent that has no effect). The investigators measured rates of all breast cancer events for five years, as well as the probability of developing invasive cancer in the same (ipsilateral) breast or the opposite (contralateral) breast. After five years, there were fewer invasive breast-cancer events in the tamoxifen group than in the placebo group in the ipsilateral and contralateral breast and at distant and regional sites. "The combination of lumpectomy, radiation therapy and tamoxifen was effective in the prevention of invasive cancer," the authors write. Related Link: tamoxifen
|